(Not Graded) Chapter 2: Pharmacological cholesterol-lowering treatment in adults but not treated with chronic dialysis or kidney transplantation (GFR categories G3a-G5), we recommend treatment with a statin or statin/ezetimibe (GFR categories G1-G2) we recommend treatment with a statin. (1B) 2.2: In adults aged 18 49 years with CKD but not treated with chronic dialysis or kidney transplantation, we suggest statin treatment in people with one or more of the following (2A): K known coronary disease (myocardial infarction or coronary revascularization) K diabetes mellitus K prior ischemic stroke K estimated 10-year incidence of coronary death or non-fatal myocardial infarction 410% 2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin/ezetimibe combination not be 2.3.2: In patients already receiving statins or statin/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (2C) 2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (2B) Chapter 3: Assessment of lipid status in children with CKD 3.1: In children with newly identified CKD (including those treated with chronic dialysis or kidney transplan- tation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, 3.2: In children with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest annual follow-up measurement of fasting lipid levels. (Not Graded) Chapter 4: Pharmacological cholesterol-lowering treatment in children 4.1: In children less than 18 years of age with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest that statins or statin/ezetimibe combination not be initiated. (2C) Chapter 5: Triglyceride-lowering treatment in adults 5.1: In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. 